JP2002532079A5 - - Google Patents

Download PDF

Info

Publication number
JP2002532079A5
JP2002532079A5 JP2000587802A JP2000587802A JP2002532079A5 JP 2002532079 A5 JP2002532079 A5 JP 2002532079A5 JP 2000587802 A JP2000587802 A JP 2000587802A JP 2000587802 A JP2000587802 A JP 2000587802A JP 2002532079 A5 JP2002532079 A5 JP 2002532079A5
Authority
JP
Japan
Prior art keywords
mbl
composition
isolated
monoclonal antibody
accession number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000587802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002532079A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1999/029919 external-priority patent/WO2000035483A1/en
Publication of JP2002532079A publication Critical patent/JP2002532079A/ja
Publication of JP2002532079A5 publication Critical patent/JP2002532079A5/ja
Pending legal-status Critical Current

Links

JP2000587802A 1998-12-15 1999-12-15 補体活性化に関連するレクチン補体経路を調節するための方法および産物 Pending JP2002532079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11239098P 1998-12-15 1998-12-15
US60/112,390 1998-12-15
PCT/US1999/029919 WO2000035483A1 (en) 1998-12-15 1999-12-15 Methods and products for regulating lectin complement pathway associated complement activation

Publications (2)

Publication Number Publication Date
JP2002532079A JP2002532079A (ja) 2002-10-02
JP2002532079A5 true JP2002532079A5 (https=) 2007-02-15

Family

ID=22343639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000587802A Pending JP2002532079A (ja) 1998-12-15 1999-12-15 補体活性化に関連するレクチン補体経路を調節するための方法および産物

Country Status (4)

Country Link
EP (1) EP1140171A4 (https=)
JP (1) JP2002532079A (https=)
CA (1) CA2347734A1 (https=)
WO (1) WO2000035483A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969601B2 (en) 1997-04-03 2005-11-29 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
CA2380979A1 (en) * 1999-08-13 2001-02-22 Brigham And Women's Hospital, Inc. Inhibitors of the lectin complement pathway (lcp) and their use
RU2003104524A (ru) * 2000-07-13 2005-01-20 Дженс Христиан ДЖЕНСЕНИУС (DK) Masp-2, комплемент-связывающий фермент и его применение
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
US20060140939A1 (en) * 2003-02-21 2006-06-29 Fung Sek C M Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
HUE024996T2 (en) 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007095154A2 (en) 2006-02-10 2007-08-23 The Brigham And Women's Hospital, Inc. Lectin complement pathway assays and related compositions and methods
EP2073898A1 (en) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Complement inhibition for improved nerve regeneration
DK2488203T3 (en) 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
EP3323830B1 (en) * 2010-06-19 2023-08-23 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BR112013025917A2 (pt) 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
RU2680267C2 (ru) 2013-03-15 2019-02-19 Мемориал Слоан Кеттеринг Кэнсер Сентер Высокоаффинные антитела к gd2
CN108588033B (zh) * 2018-04-24 2021-09-24 富恩生物技术（成都）有限公司 杂交瘤细胞株、cd31单克隆抗体、制备方法及应用
CN115120705B (zh) * 2022-07-07 2025-01-28 新乡医学院 甘露聚糖结合凝集素在抑制细胞衰老方面的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270199A (en) 1987-08-20 1993-12-14 The Children's Medical Center Corporation Human mannose-binding protein
FI900808A7 (fi) * 1987-08-20 1990-02-19 Childrens Medical Center Ihmisen mannoosia sitova proteiini
DE3927723A1 (de) * 1989-01-26 1990-08-02 Ulrich Prof Dr Speck N - acetylglucosamin zur buccalen anwendung
WO1991006010A1 (en) * 1989-10-11 1991-05-02 Institute Of Child Health Diagnostic procedure
WO1993018775A1 (en) * 1992-03-19 1993-09-30 The University Of British Columbia Method and composition for suppression of side effects of anti-inflammatory drugs
JPH06121695A (ja) * 1992-10-13 1994-05-06 Fuji Yakuhin Kogyo Kk 抗ヒトマンノース結合蛋白モノクローナル抗体およびその利用
JPH07238100A (ja) * 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5998173A (en) * 1996-02-20 1999-12-07 The University Of Bristish Columbia Process for producing N-acetyl-D-glucosamine

Similar Documents

Publication Publication Date Title
JP2002532079A5 (https=)
JP4716350B2 (ja) 潜伏期膜タンパク質に対する抗体およびそれらの使用
DK2298348T3 (en) Antibody-binding alpha4Beta7 integrin and its use in the treatment of inflammatory bowel disease
JP2022104941A (ja) ヒト化抗ｃｄ７３抗体
JP7734720B2 (ja) Ｍｉｃａ／ｂシェディングをブロックする抗ｍｉｃａ／ｂ抗体および使用方法
Yang et al. Differential expression of CD8 epitopes amongst porcine CD8‐positive functional lymphocyte subsets
Zone et al. IgA autoimmune disorders: development of a passive transfer mouse model
RU2006115835A (ru) Человеческие антитела против человеческого 4-1вв (cd137)
JP2002511424A5 (https=)
US6291239B1 (en) Monoclonal antibody
JP2004517611A5 (https=)
EP3679070A1 (en) Antibodies to programmed cell death protein 1
JP2005505256A5 (https=)
JP2010501164A5 (https=)
WO2002085946A1 (en) Bispecific antibodies that bind trail-r1 and trail-r2
US5480974A (en) Antibodies to human C5a receptor
JP2023544143A5 (https=)
JPH08504170A (ja) 進行性免疫抑制症患者の評価と治療
AU665783B2 (en) Anti-alpha6-integrin-antibodies
KR20080059449A (ko) 치료용 약제
JP2003523735A5 (https=)
JP2003523735A (ja) ヒトナチュラルキラー細胞によって媒介される天然細胞毒性に関連した新規トリガリングレセプターおよび同一の性質を有する抗体
WO1994012631A1 (en) Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors
JP2018532427A (ja) 抗ｃｄ９５ｌ抗体
KR20140043795A (ko) 가용성 인테그린 α4 변이체